n n n ‘.concat(e.i18n.t(“search.voice.recognition_retry”),’n
Validity of the CureVac EP 1 857 122 B1 patent denied by the German Federal Patent Court following a invalidity action filed through BioNTech SE
The resolution does not address ongoing litigation in Germany over seven other intellectual asset rights, covering strong core and mRNA-specific innovations from COVID-19.
CureVac will appeal to Germany’s Federal Court of Justice, while remaining confident in the strength of its extensive portfolio of intellectual assets.
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / December 19, 2023 / CureVac N. V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company introducing a new generation of messenger ribonucleic acid (“mRNA”) transforming medicines , announced that BioNTech SE’s invalidation action against the German part of the CureVac patent EP 1,857,122 B1 has been granted through the German Federal Patent Court. CureVac will appeal to the German Federal Court of Justice.
This resolution represents a first ruling on validity in an ongoing patent dispute between CureVac and BioNTech SE in Germany, amounting to a total of 8 CureVac intellectual asset rights. The procedure continues with respect to the remaining seven rights, the validity, infringement and possible damages will be individual. As a result of today’s ruling, the judgment on the infringement of the German component of patent EP 1. 857. 122 B1, scheduled for December 28, 2023 before the Düsseldorf Regional Court, will likely be postponed.
“We take into consideration the Patent Court’s ruling, also unfortunate in view of the initial positive ruling on patent EP 1,857,122 B1 that the court issued earlier this year. The resolution is just one of many that will be taken in connection with the use of CureVac’s intellectual assets in the development of Comirnaty®. We remain confident that our pioneering role in mRNA generation and our continued innovation in this domain have made critical contributions to achieving safe and effective COVID-19 vaccines,” said Dr. Alexander Zehnder, CEO of CureVac. While we do not seek to decrease the price of mRNA vaccines to replace the course of the COVID-19 pandemic, we strongly believe that CureVac’s role in building the clinical foundation for those vaccines will need to be recognized for fair popularity and reimbursement and we will take appropriate action through a nice resolution.
CureVac is represented in Germany by Oliver Jan Jüngst of Bird
About CureVac
CureVac (Nasdaq:CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium, Switzerland and the U.S. Further information can be found at www.curevac.com.
CureVac Media & Investor Relations
Dr. Sarah Fakih, Vice President of Corporate Communications and Investor RelationsCureVac, Tübingen, GermanyT: 49 7071 9883-1298M: 49 160 496949sarah. fakih@curevac. com
Forward-Looking Statements CureVac
This press release includes statements that constitute “forward-looking statements” as that term is explained in the Private Securities Litigation Reform Act of 1995, including statements that express opinions, expectations, ideals, plans, objectives, assumptions or projections. by CureVac N. V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc. , CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Nederlands B. V. (the “Company”) in respect of long-term occasions or performance occasions. effects, contrary to statements that reflect old facts. The examples come with a discussion of the potential effectiveness of the company’s vaccine and remedy applicants, as well as the company’s strategies, financing plans, expansion opportunities, and expanding market position. In some cases, you can identify such forward-looking statements by terms such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect. ” , “will”, “would”, “may also”, “prospective”, “intends” or “deserves”, the negative form of those terms or similar explicit ones. Forward-looking statements are based on management’s existing ideals and assumptions and the current configuration of the Company. However, such forward-looking statements are not guarantees of the Company’s performance and you should not place undue reliance on them. Forward-looking statements are subject to a variety of risks, uncertainties and other varying circumstances, including negative global economic situations and continued instability and volatility in global money market positions, the ability to discharge financing, the ability to conduct preclinical studies and the current and long-term. execute clinical trials, timing, expense and uncertainty of regulatory approval, dependence on third parties and collaboration partners, ability to commercialize products, ability to manufacture products. Arrange conceivable adjustments to existing and proposed legislation, regulations and government policies, pressures similar to festival expansion and consolidation within the business. industry, effects of the COVID-19 pandemic on the Company’s business and operational effects, ability to manage expansion, dependence on key personnel, dependence on intellectual property coverage, ability to ensure patient safety, fluctuations in operational effects due to the effect of exchange rates, delays in legal proceedings, different legal results or other points. Such dangers and uncertainties could cause the statements to be misleading and readers are cautioned not to place undue reliance on such statements. Many of these hazards are beyond the Company’s control and may also cause their actual effects to differ materially from those expected to occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not assume, and in particular disclaims, any legal responsibility to update such statements or to publicly announce the effects of any revisions to such statements to reflect long-term events or developments, unless required by law.
For more information, please refer to the Company’s reports and documents filed with the U. S. Securities and Exchange Commission. U. S. Securities and Exchange Commission (SEC). You can download those documents by visiting EDGAR at the SEC in www. sec. gov.
SOURCE: CureVac NV
Read the original press on accesswire. com